Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Eylea | Aflibercept | Macular degeneration, age-related | List with criteria/condition | Complete | ||
Diacomit | Stiripentol | Dravet Syndrome | List with criteria/condition | Complete | ||
Stelara | Ustekinumab | Arthritis, psoriatic | Do not list at the submitted price | Complete | ||
Breo Ellipta | Fluticasone furoate /vilanterol | Chronic Obstructive Pulmonary Disease (COPD) | List with criteria/condition | Complete | ||
Tivicay | Dolutegravir | HIV infection | List | Complete | ||
Stivarga (GIST) | Regorafenib | Gastrointestinal Stromal Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | Withdrawn | |||
Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete | ||
Sovaldi | Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete |